Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 5, 2000, Pages 528-532

  Dickens, George R ^a   Wermeling, Daniel P ^a   Matheny, Christopher J ^a   John, William ^a   Abramowitz, Wattanaporn ^b   Sista, Suryanarayana M ^b   Foster, Thomas ^a   Choudhury, Somesh ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUNISOLIDE;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; MALE; METERED DOSE INHALER; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034094429     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)62517-3     Document Type: Article

References (14)

1. Lötvall J. Local versus systemic effects of inhaled drugs. Resp Med 1997; 91(Suppl A):29-31.
2. Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax 1994;49:549-553.
3. Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984;129: 723-729.
4. Newman SP, Moren F, Pavia D, et al. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis 1981;124: 317-320.
5. Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996;51: 835-840.
6. O'Callaghan C. Delivery systems: the science. Pediatr Pulmonol 1997; 15(Suppl):51-54.
7. Mollmann H, Derendorf H, Barth J, et al. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 1997;37:893-903.
8. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332: 868-875.
9. Craig T. Use of spacer devices with inhaled steroids. Arch Intern Med 1995;155:547-548.
10. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-110.
11. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101:S440-S446.
12. Chaplin MD, Rooks W, Swenson EW, et al. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980;27:402-413.
13. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998; 32:220-232.
14. Barry PW, O'Callaghan C. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Eur Respir J 1997;10: 1345-1348.